Hot off the presses! Jul 01 Nat Rev Cancer

The Jul 01 issue of the Nat Rev Cancer is now up on Pubget (About Nat Rev Cancer): if you're at a subscribing institution, just click the link in the latest link at the home page. (Note you'll only be able to get all the PDFs in the issue if your institution subscribes to Pubget.)

Latest Articles Include:

• From the editors
  - Nat Rev Cancer 9(7):453 (2009)
  
• Signalling: Hedgehog doesn't...
  - Nat Rev Cancer 9(7):455 (2009)
  
• Senescence: Playing games with epigenetics
  - Nat Rev Cancer 9(7):456 (2009)
  
• Angiogenesis: How Down's syndrome protects
  - Nat Rev Cancer 9(7):456 (2009)
  
• Therapeutics: Dependent on KRAS
  - Nat Rev Cancer 9(7):457 (2009)
  
• Breast cancer: Prioritizing targets
  - Nat Rev Cancer 9(7):458 (2009)
  
• Drug resistance: Getting through
  - Nat Rev Cancer 9(7):458 (2009)
  
• Canine first
  - Nat Rev Cancer 9(7):458 (2009)
  
• In brief: Metastasis, Tumorigenesis, Non-coding RNA, Tumour initiation
  - Nat Rev Cancer 9(7):459 (2009)
  
• Breast cancer: Metastasis on the brain
  - Nat Rev Cancer 9(7):460 (2009)
  
• Breast cancer: A DEAR 1
  - Nat Rev Cancer 9(7):460 (2009)
  
• Epigenetics: Misreading the code
  - Nat Rev Cancer 9(7):461 (2009)
  
• Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
  - Nat Rev Cancer 9(7):463-475 (2009)
  Aberrant receptor expression or functioning of the epidermal growth factor receptor (Erbb) family plays a crucial part in the development and evolution of cancer. Inhibiting the signalling activity of individual receptors in this family has advanced the treatment of a range of human cancers. In this Review we re-evaluate the role of two important family members, ERBB2 (also known as HER2) and ERBB3 (also known as HER3), and explore the mechanisms of action and preclinical and clinical data for new therapies that target signalling through these pivotal receptors. These new therapies include tyrosine kinase inhibitors, antibody–chemotherapy conjugates, heat-shock protein inhibitors and antibodies that interfere with the formation of ERBB2–ERBB3 dimers.
• Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers
  - Nat Rev Cancer 9(7):476-488 (2009)
  Chemoprevention of lung carcinogenesis is one approach to controlling the epidemic of lung cancer caused by cigarette smoking. The target for chemoprevention should be the activities of the multiple carcinogens, toxicants, co-carcinogens, tumour promoters and inflammatory compounds in cigarette smoke. At present there are many agents, both synthetic and naturally occurring, that prevent lung tumour development in well-established animal models. It seems likely that logically constructed mixtures of these agents, developed from the ground up, will be necessary for the prevention of lung carcinogenesis.
• Genetic prognostic and predictive markers in colorectal cancer
  - Nat Rev Cancer 9(7):489-499 (2009)
  Despite many studies of the likely survival outcome of individual patients with colorectal cancer, our knowledge of this subject remains poor. Until recently, we had virtually no understanding of individual responses to therapy, but the discovery of the KRAS mutation as a marker of probable failure of epidermal growth factor receptor (EGFR)-targeted therapy is a first step in the tailoring of treatment to the individual. With the application of molecular analyses, as well as the ability to perform high-throughput screens, there has been an explosive increase in the number of markers thought to be associated with prognosis and treatment outcome in this disease. In this Review, we attempt to summarize the sometimes confusing findings, and critically assess those markers already in the public domain.
• Apoptosis and cancer: the genesis of a research field
  - Nat Rev Cancer 9(7):501-507 (2009)
  In multicellular organisms, the total number of cells is a balance between the cell-generating effects of mitosis and cell death that is induced through apoptosis. A disruption of this delicate balance can lead to the development of cancer. This Timeline article focuses on how the field of apoptosis biology has developed in the context of its contribution to our understanding of cell death, or lack of it, in the development of malignant disease. It traces the course of research from key discoveries in fundamental biology to potential therapeutic applications.
• Cancer prevention research — then and now
  - Nat Rev Cancer 9(7):508-516 (2009)
  Throughout history, humankind has won the battle against deadly diseases, including small pox and polio, by defeating them through prevention. Cancer prevention is a global priority, but studying history suggests that the journey towards achieving this goal is difficult and full of detours and roadblocks. Epidemiology and clinical evidence clearly indicate that specific genetic, environmental and behavioural factors are associated with an increased risk for cancer development. What can we learn from the past that is applicable to the reality of successful cancer prevention?
• Wildlife cancer: a conservation perspective
  - Nat Rev Cancer 9(7):517-526 (2009)
  Until recently, cancer in wildlife was not considered to be a conservation concern. However, with the identification of Tasmanian devil facial tumour disease, sea turtle fibropapillomatosis and sea lion genital carcinoma, it has become apparent that neoplasia can be highly prevalent and have considerable effects on some species. It is also clear that anthropogenic activities contribute to the development of neoplasia in wildlife species, such as beluga whales and bottom-dwelling fish, making them sensitive sentinels of disturbed environments.